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Available online 21 August 2006Abstract—A series of acetaminophen (APAP) analogs, 2-(1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl)-N-(4-hydroxyphe-
nyl)alkanecarboxamides, bearing a heterocyclic moiety linked to the p-acylaminophenol fragment, were prepared in a general pro-
ject to develop APAP analogs with modulated pharmacokinetic proﬁles. Unexpectedly, the products described maintained the
in vivo analgesic proﬁle, while the characteristic hepatotoxicity of APAP was consistently reduced. One of the products, 5a, was
studied in vivo in comparison with APAP. Compound 5a displayed an analgesic eﬃcacy comparable to that of APAP. A relatively
high acute oral dose of 5a (6 mmol/kg) produced no measurable toxicity, whereas the equimolar dose of APAP increased transam-
inase activity, depleted hepatic and renal glutathione, and resulted in mortality. In human hepatocytes (HEPG-2) and in human
primary cultures of normal liver cells, APAP, but not 5a, was associated with apoptotic cell death, Fas-ligand up-regulation,
and CAR (constitutive androstane receptor) activation, contributing to a favorable safety proﬁle of 5a as an orally delivered
analgesic.
 2006 Elsevier Ltd. All rights reserved.1. Introduction
Because of the relatively low incidence of gastrointesti-
nal and hypersensitivity reactions at normal therapeutic
doses, acetaminophen (APAP, Fig. 1) is considered to be
the drug of choice for mild to moderate pain that is not
caused by inﬂammation.1 Despite its widespread use, the
mechanisms that mediate the analgesic and antipyretic
eﬀects of APAP are not entirely understood. Although
in vitro studies have demonstrated an ability of APAP
to inhibit cyclooxygenase-1 and -2 (COX-1 and -2),2,3
its weak anti-inﬂammatory activity as compared with
that of non-steroidal anti-inﬂammatory drugs (NSA-0968-0896/$ - see front matter  2006 Elsevier Ltd. All rights reserved.
doi:10.1016/j.bmc.2006.07.054
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 These authors contributed equally to this work.IDs) suggests that other non-COX-related mechanisms
also are involved.4–6 More recently, the pharmacological
eﬀects of APAP have been suggested to be related to the
formation of a metabolite (AM404, Fig. 1) that inter-
feres with targets involved in pain and thermoregula-
tion, including COX-mediated prostaglandin synthesis,
and vanilloid and cannabinoid receptor systems.7
Although APAP shows low incidence of gastrointestinal
and other COX-related adverse eﬀects as compared with
most NSAIDs, it is well established that APAP can
cause hepatotoxicity8 and nephrotoxicity. These eﬀects
can potentially be lethal,9,10 particularly after ingestion
of large doses or after chronic use of small doses when
liver function is already compromised (e.g., in the elder-
ly and in patients with alcoholic liver disease). Although
it is likely that multiple pathways lead to APAP-induced
hepatotoxicity,11 oxidation of APAP to the correspond-
ing N-acetyl-p-benzoquinone imine (NAPQI) is likely a
Figure 1. Structures of APAP, NO-APAP, AM 404, and the new acetaminophen analogs 5.
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APAP up-regulates liver Fas and Fas-ligand mRNA
expression in vivo, suggesting that APAP liver toxicity
is mediated through the Fas pathway.13 In addition,
the xenobiotic receptor CAR (constitutive androstane
receptor) has been identiﬁed as a critical regulator of
APAP-induced hepatotoxicity, since high doses of
APAP induce hepatotoxicity in wild-type mice but not
in CAR-null mice; this toxicity is blocked by the CAR
antagonist, androstanol.14
Upon exploring the idea of modulating the pharmacoki-
netic proﬁle of the product, a series of compounds bear-
ing the APAP fragment, linked to diﬀerent lipophilic
heterocyclic moieties, was synthesized.15,16 Unexpected-
ly,when the products were tested, some of them were de-
void of hepatotoxicity. We describe here the synthesis,
in vivo analgesic eﬃcacy, and toxicity of several com-
pounds, 2-(1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-
yl)-N-(4-hydroxyphenyl) alkanecarboxamides 5a–e
(Fig. 1). The 1,1-dioxo-1,2-dihydrobenzo[d]isothiazol-
3-one-2-yl moiety is a heterocyclic fragment, which has
been extensively used in medicinal chemistry. Such a
strategy was expected to lead to the development of
compounds with diﬀerent distribution and in vivo prop-
erties. In practice, however, one of them, 5a (SCP-1),
has a shorter elimination half-life and clearance than
does APAP in isolated rat hepatocytes,17 which could
yield a more favorable hepatotoxic proﬁle for the
product.Scheme 1. Synthesis of compounds 5. Method A. Reagents and conditions:2. Chemistry
Compound 5a was part of a general project testing li-
braries of new lipophilic acetaminophen analogs,15,16
with heterocyclic fragments linked to the characteristic
acylamino(4-hydroxy)phenyl group, essential in APAP.
Unexpectedly, a series was identiﬁed with reduced hepa-
totoxicity, in which the heterocycle is the 2-(2,3-dihydro-
3-oxo-1,2-benzisothiazol-2-yl-1,1-dioxide) linked to the
essential fragment by a polymethylene chain, modiﬁed
by homology, along the set of compounds 5 (Fig. 1).
The products 5 were prepared according to two alterna-
tive methods. Method A (Scheme 1) started by acylation
of p-aminophenol 2 with the corresponding x-haloal-
kanecarbonyl chloride 1, to produce the chloroaceta-
mide 3, which was then reacted with sodium saccharin
4, to produce the corresponding compounds 5a, b, and
c. Method B started with the alkylation of the sodium
saccharin 4 with the corresponding x-haloalkanecarb-
oxylic acid 6, to produce the acid 7, which was then used
to acylate the aminophenol 2, producing 5d and e
(Scheme 2).3. Results and discussion
An initial comparison of the series 5, based on oral anal-
gesic and hepatotoxic activities, was made to determine
which compound would be selected for additional
characterization. Table 1 shows the analgesic (acetic(a) AcOH, aq NaAcO, 5 C; (b) DMF, 2 h reﬂux.
Scheme 2. Synthesis of compounds 5. Method B. Reagents and conditions: (c) DMF, 3 h, reﬂux; (d) Cl2CH2, 1-hydroxy-benzotriazole, DCC 2 h, rt.
Table 1. Comparison of analgesic and hepatotoxic eﬀects of com-
pounds 5 and APAP
Compound n Writhing assaya Plasma GPTb
5a 1 62.42 ± 9.45 30.50 ± 5.05
5b 2 43.80 ± 12.59 28.85 ± 4.31
5c 3 28.90 ± 13.41 82.62 ± 29.98
5d 4 32.56 ± 12.79 44.16 ± 16.32
5e 5 53.72 ± 11.78 29.52 ± 5.42
APAP 61.32 ± 12.45 299.01 ± 44.30
a Analgesic eﬀects (% analgesia ± SEM) were measured 1 h following a
1 mmol/kg oral dose of each compound (CD-1 mice, n = 9–16 per
group).
b Plasma GPT (spectrophotometric SF units/mL ± SD) was measured
24 h after a 3.7 mmol/kg oral dose of each compound (control lev-
els = 24.42 ± 2.25). In a pilot study, 3.7 mmol/kg was established as
the LD50 for APAP in this strain of mouse (C57BL/6).
Figure 2. Analgesic eﬀects of SCP-1 and APAP in the writhing assay in
mice. Data are expressed as percent analgesia relative to vehicle-treated
control (±SEM) 30–40 min after administration of diﬀerent oral doses
of 5a or APAP.
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tamic–pyruvic transaminase (GPT))19 properties of
compounds 5 and APAP as standard, following oral
administration of an equimolar test dose. All com-
pounds 5 demonstrated analgesic activity in the writhing
assay, with 5a showing activity comparable to APAP.
Furthermore, all compounds 5 displayed little or no
eﬀect on plasma GPT levels, indicating that they are
not hepatotoxic. This is in contrast to APAP, which pro-
duced a relatively large increase in plasma GPT (9.8-fold
increase over 5a). On the basis of its favorable analgesic
activity and potential lack of toxicity, 5a was selected as
the prototype of this series for further biological and
pharmacological characterization.
A systematic screening to evaluate the in vivo analgesic
eﬃcacy of 5a, as compared to that of APAP, was per-
formed. In the chemically induced writhing assay,18
both 5a and APAP produced dose-dependent analgesic
eﬀects in mice (Fig. 2). On a molar basis, 5a
(ED50 = 640 lmol/kg, r
2 = 0.97, p < 0.01) was 2.01-fold
more potent than APAP (ED50 = 1290 lmol/kg,
r2 = 0.86, p < 0.01). Dose–response relations in the for-
malin-induced pain assay20 in mice are shown in Figure
3A (5a) and Figure 3B (APAP). Both 5a (SCP-1) andAPAP produced dose-dependent analgesic eﬀects, with
5a (ED50 = 260 lmol/kg, r
2 = 0.29, p < 0.01) being 7.3-
fold more potent than APAP (ED50 = 1903 lmol/kg,
r2 = 0.35, p < 0.01). In the tail-ﬂick21 or hot plate22
assays in mice, neither 5a (doses up to 3010 lmol/kg)
nor APAP (doses up to 6620 lmol/kg) was eﬀective
(data not shown), a ﬁnding that is consistent with previ-
ous studies that have demonstrated no or weak analgesic
activity of APAP in these assay.23 Moreover, neither 5a
nor APAP was found to possess anti-inﬂammatory
properties in a model of carrageenan-induced paw
edema24 (Fig. 4).
To evaluate 5a hepatotoxicity and nephrotoxicity, ser-
um GPT levels and glutathione concentrations in liver
and kidney homogenates were measured after a high
acute dose (6 mmol/kg) of either 5a or APAP. Glutam-
ic–oxaloacetic transaminase (GOT) activity was also
measured as an index of more general toxic eﬀects on
such organs as heart, muscle, and spleen.25 Compound
5a did not induce signs of liver or kidney damage, as
demonstrated by unchanged hepatic and renal glutathi-
one levels (Fig. 5A) and plasma GPT and GOT concen-
trations (Fig. 5B), as compared with vehicle-treated
controls. In contrast, APAP caused signiﬁcant changes
in these markers, reducing hepatic and renal glutathione
levels and increasing plasma GPT and GOT. Further-
more, this dose of APAP (6 mmol/kg) resulted in 40%
(4/10) mortality, whereas none of the mice treated with
Figure 3. Analgesic eﬀects of SCP-1 (A) and APAP (B) in the formalin
assay in mice treated 30 min before formalin injection. Data are
expressed as mean time (±SEM) spent licking the injected paw for each
5-min interval during the 90 min after formalin injection. (See ﬁgure
for sample sizes.)
Figure 5. Eﬀects of 6 mmol/kg SCP-1 and APAP on liver and kidney
glutathione (A), and GPT and GOT levels (B) (n = 8–12 mice in each
assay).
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thione levels under conditions in which APAP does, it
can be concluded that 5a does not produce NAPQI
(or the corresponding NAPQI analog), a proﬁle that
would favor decreased hepatotoxicity.
The hepatotoxic eﬀects of 5a were evaluated further in
human hepatocytes (HEPG-2) and in primary cultures
of normal human liver cells (Fig. 6). In HEPG-2 cells,Figure 4. Anti-inﬂammatory eﬀects of SCP-1, APAP (n = 4–5 mice per
dose), and indomethacin (inset, n = 8 per group) on carrageenan-
induced paw edema in mice treated 30 min before carrageenan
treatment. Data are expressed as percentage of vehicle-treated controls
(±SEM) 4 h after injection of carrageenan into one hind paw.5a produced no hepatotoxic eﬀects. In contrast, APAP
caused severe hepatocyte damage, and NO-APAP
(Fig. 1), a nitrate ester derivative of APAP,26 caused
an intermediate level of damage in these cells. This liver
damage was associated with apoptotic cell death as evi-
denced by the observation that APAP, unlike 5a, pro-
moted enhanced apoptosis in both HEPG-2 cells (Figs.
6A and B) and in primary cultures of human hepato-
cytes (Figs. 6E and F), while NO-APAP promoted an
intermediate level of apoptosis. In this study, we con-
ﬁrmed that APAP up-regulated Fas-ligand in both
HEPG-2 cells (Fig. 6C) and primary liver cells
(Fig. 6G). In contrast, 5a did not up-regulate the Fas-li-
gand in these cells (Figs. 6C and G). Tunel and DNA
fragmentation as described elsewhere,27 as additional
apoptosis markers,28 followed similar trends of changes
(data not shown), as did those of the reported assays. In
addition, 5a did not activate CAR in HEPG-2 cells
(Fig. 6D) or in normal liver cells (Fig. 6H), as compared
with APAP (and NO-APAP), which strongly activated
this receptor (Figs. 6D and H).
To determine whether the actions of 5a could be ex-
plained by its conversion to APAP, the metabolites gen-
erated from 5a were analyzed in samples of mouse urine
after a single administration po of 5a, 3 mmol/kg. Urine
was collected for 24 h and analyzed by HPLC–MS, and
every peak of the chromatogram was identiﬁed. The
main metabolites detected in mouse urine are indicated
in Scheme 3 and expressed as percentage of total
Figure 6. Trypan blue exclusion test indicated that 5a did not induce toxicity in HEPG-2 cells (A). In contrast, APAP induced severe hepatotoxicity
at concentrations of 100 and 200 lM. APAP induced apoptotic cell death as measured by Hoechst staining (2 lM ﬁnal concentration) in 100 lM
APAP-treated (6–8 h) HEPG-2 cells. NO-APAP caused an intermediate level of cell death, whereas 5a was ineﬀective in inducing cell death (B).
Time-dependent up-regulation of Fas-ligand showed that APAP caused the highest up-regulation of Fas-ligand in HEPG-2 cells treated with 100 lM
acetaminophen for the time indicated; NO-APAP caused an intermediate level of up-regulation; and 5a was similar to controls (C). Time-dependent
induction of xenobiotic receptor CAR (constitutive androstane receptor), a key regulator of APAP-mediated hepatotoxicity, was measured in
HEPG-2 cells treated with 100 lM APAP, 5a, and NO-APAP for the times indicated. Quantitation of CAR protein levels by densitometry showed
that 5a was unable to activate CAR, which remained at the control level throughout the entire period of the treatment (D). (E) Analysis of the
hepatotoxic eﬀects of 5a, APAP, and NO-APAP on primary cultures of human liver cells measured by the Trypan blue exclusion method showed that
the hepatotoxic eﬀects exerted by these compounds were comparable to those in HEPG-2 cells, as indicated in A and B. APAP, unlike 5a, caused
enhanced apoptosis in primary liver culture as detected by Hoechst staining, while NO-APAP promoted an intermediate level of apoptosis (F). Pro-
apoptotic Fas-ligand up-regulation was signiﬁcantly enhanced by APAP in human primary liver cultures, whereas 5a had no eﬀect (G). CAR was
unaﬀected by 5a in human hepatocyte cultures, but was strongly activated by APAP; an intermediate level of activation was produced by NO-APAP
(H).
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(0.9%) is excreted by urine, the major metabolite was
the hydrolysis product 8 (38.6%). Although no reference
samples were available, both 5a and 8 apparently formed
the corresponding glucuronates 9 (32%) and 10 (23.7%).
To be used as a reference product, 8was prepared by basic
hydrolysis of 5a (Scheme 4). Alternatively, 5a resisted one
hour reﬂux in HCl without decomposition.
Both 5a and 8 were used in HPLC–MS experiments to
identify the peaks in the urine samples. As a whole, these
results indicate that 5a and APAP are metabolized
through diﬀerent pathways, and that 5a is not simply
a ‘pro-drug’ of APAP. On the other hand, 5a seems to
be easily metabolized in vivo, generating a comparative-
ly hydrosoluble compound 8, easily eliminated by urine.Work is in progress to determine whether this metabolic
pathway could be related to the reduced hepatotoxicity
of 5 derivatives.4. Conclusion
In summary, our results demonstrate that 5a has good
oral analgesic eﬃcacy, as measured in the formalin and
chemically inducedwrithing assays.When comparedwith
APAP on a molar basis, 5a was typically a more potent
analgesic (2- to 7-fold). Furthermore, the decreased
induction of Fas-ligand and CAR by 5a is consistent with
reduced hepatotoxicity, thus contributing to the safety
proﬁle of 5a as a potential orally delivered analgesic for
the treatment of various pain states in humans.
Figure 6. (continued)
Scheme 3. Metabolites of 5a detected in mouse urine.
Scheme 4. Synthesis of 5a main metabolite. Reagents and conditions: (e) H2O, NaOH, 20 min, rt.
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5.1. Materials
Melting points were recorded on an Electrothermal
IA6304 instrument and are uncorrected. IR spectra
were obtained on a Perkin-Elmer FTIR 1725X spec-
trometer. 1H NMR spectra were obtained on a Var-
ian Unity 300 spectrometer at 300 MHz. HPLC–MS
analyses were performed on an Agilent 1100 appara-
tus. Flash chromatography was conducted using
Merck Kieselgel 60 (230–400 mesh). Solvents andreagents were of commercial origin, and were puriﬁed
by standard procedures.
5.2. Chemistry
5.2.1. Method A
5.2.1.1. General procedure for the synthesis of N-(4-
hydroxyphenyl)-x-haloalkane-carboxamides (3).The cor-
responding x-haloalkaneacylchloride (1, 65 mmol) was
added dropwise to a solution of 4-aminophenol (2,
6.5 g, 54 mmol), acetic acid (45 mL), and a saturated
solution of sodium acetate (45 mL) at 5 C. After the
2212 A. L. Vaccarino et al. / Bioorg. Med. Chem. 15 (2007) 2206–2215addition was completed, the mixture was stirred at 0 C
for 2 h and then ﬁltered to give a white solid. The solid
was recrystallized from water to yield 3 as a colorless
crystalline solid.
5.2.1.2. N-(4-Hydroxyphenyl)-2-chloroacetamide (3a).
The general method was applied to chloroacetylchloride
(1a, 6.7 g, 65 mmol). The product 3a was obtained as a
colorless crystalline solid (7.6 g, 69% yield). Mp 144–
146 C. 1H NMR (DMSO-d6, 300 MHz) d: 10.04 (s,
1H, NH), 9.27 (s, 1H, OH), 7.36 (d, 2H, J = 8.6 Hz,
H-2,6 p-aminophenol), 6.71 (d, 2H, J = 8.6 Hz, H-3,5
p-aminophenol), 4.19 (s, 2H, CH2). Anal. Calcd for
C8H8ClNO2: C, 51.77; H, 4.34; N, 7.55; Cl, 19,10.
Found, C, 51.56; H, 4.57; N, 7.36; Cl, 19.33.
5.2.1.3. N-(4-Hydroxyphenyl)-3-bromopropionamide
(3b). The general method was applied to 3-bromopropi-
onyl chloride (1b, 11 g, 65 mmol), yielding 3b as a color-
less crystalline solid (8.2 g, 63% yield). Mp 130–132 C.
1H NMR (DMSO-d6, 300 MHz) d: 9.79 (s, 1H, NH),
9.18 (s, 1H, OH), 7.37 (d, 2H, J = 8.7 Hz, H-2,6 p-ami-
nophenol), 6.79 (d, 2H, J = 8.7 Hz, H-3,5 p-aminophe-
nol), 3.71 (t, 2H, C(a)H2), 2.89 (t, 2H, C(b)H2). Anal.
Calcd for C9H10BrNO2: C, 44.29; H, 4.13; N, 5.74; Br,
32,74. Found, C, 44.46; H, 4.17; N, 5.56; Br, 32.53.
5.2.1.4. N-(4-Hydroxyphenyl)-4-chlorobutyrylamide
(3c). The general method was applied to 4-chlorobuty-
rylchloride (1c, 9.2 g, 65 mmol), to yield 3c as colorless
crystalline solid (6.5 g, 56% yield). Mp 112–114 C. 1H
NMR (DMSO-d6, 300 MHz) d: 9.69 (s, 1H, NH), 9.17
(s, 1H, OH), 7.35(d, 2H, J = 8.8 Hz, H-2,6 p-aminophe-
nol), 6.68 (d, 2H, J = 8.8 Hz, H-3,5 p-aminophenol),
3.68 (t, 2H, C(a)H2), 2.41 (t, 2H, C(v)H2), 2.25 (m,
2H, C(b)H2). Anal. Calcd for C10H12ClNO2: C, 56.21;
H, 5.66; N, 6.56; Cl, 16,59. Found, C, 56.40; H, 5.57;
N, 6.66; Cl, 16.53.
5.2.1.5. General procedure for the synthesis of N-(4-
hydroxyphenyl)-2-[2,3-dihydro-3-oxo-1,2-benzisothiazol-
2-yl-1,1-dioxide]-alkanecarboxamides (5). A solution
of N-(4-hydroxyphenyl)-x-haloalkanecarboxamide (3,
20 mmol) and sodium saccharin (4, 6.2 g, 30 mmol) in
DMF (16 mL) was heated to reﬂux with stirring for
2 h. At the end of this time, the NaCl that precipitated
was removed by ﬁltration and the ﬁltrate was evaporat-
ed under reduced pressure. The residue was partitioned
between EtOAc (180 mL) and water (100 mL). The
organic layer was washed with brine (100 mL) and dried
(Na2SO4), and the solvent was removed under reduced
pressure to aﬀord a white solid. The crude solid was
recrystallized from ethanol/H2O (8:1) to furnish 5 as a
colorless crystalline solid.
5.2.1.6. N-(4-Hydroxyphenyl)-2-[2,3-dihydro-3-oxo-
1,2-benzisothiazol-2-yl-1,1-dioxide]-acetamide (5a). The
general method was applied to N-(4-hydroxyphenyl)-2-
chloroacetamide (3a, 3.7 g, 20 mmol) to yield 5a as a col-
orless crystalline solid (5.7 g, 86%). Mp 204–206 C. IR
(KBr, cm1); 3339, 3100, 1742, 1676, 1509, 1449, 1332,
1185, 1063. 1H NMR (DMSO-d6, 300 MHz) d: 10.06 (s,
1H, NH), 9.27 (s, 1H, OH), 8.33 (d, 1H, J = 7.4 Hz, H-4of 2-[2,3-dihydro-3-oxo-1,2-benzisothiazol-2-yl-1,1-di-
oxide]), 8.16–7.95 (m, 3H, H-5,6,7 of 2-[2,3-dihydro-3-
oxo-1,2-benzisothiazol-2-yl-1,1-dioxide]), 7.31 (d, 2H,
J = 8.7 Hz, H-2,6 p-aminophenol), 6.68 (d, 2H,
J = 8.7 Hz, H-3,5 p-aminophenol), 4.49 (s, 2H, CH2).
Anal. Calcd for C15H12N2O5S: C, 54.21; H, 3.64; N,
8.43; S, 9.65. Found, C, 54.16; H, 3.77; N, 8.36; S, 9.48.
5.2.1.7. N-(4-Hydroxyphenyl)-3-[2,3-dihydro-3-oxo-
1,2-benzisothiazol-2-yl-1,1-dioxide]-propionamide (5b).
The general method was applied to N-(4-hydroxyphe-
nyl)-3-bromopropionamide (3b) (4.9 g, 20 mmol) to
yield 5b as a colorless crystalline solid (5.9 g, 85%).
Mp 237–239 C, IR (KBr, cm1); 3382, 1746, 1648,
1551, 1438, 1312, 1174, 1157. 1H NMR (DMSO-d6,
300 MHz) d: 9.78 (s, 1H, NH), 9.16 (s, 1H, OH), 8.28
(d, 1H, J = 6.9 Hz, 4-H of 2-[2,3-dihydro-3-oxo-1,2-
benzisothiazol-2-yl-1,1-dioxide]), 8.11–7.95 (m, 3H,
H-5,6,7 of 2-[2,3-dihydro-3-oxo-1,2-benzisothiazol-2-yl-
1,1-dioxide]), 7.29 (d, 2H, J = 8.7 Hz, H-2,6 p-aminophe-
nol), 6.67 (d, 2H, J = 8.7 Hz, H-3,5 p-aminophenol), 4.03
(t, 2H, J = 7.3 Hz, C(a)H2), 2.77 (t, 2H, J = 7.6 Hz,
C(b)H2). Anal. Calcd for C16H14N2O5S: C, 55.48; H,
4.07; N, 8.08; S, 9.26. Found: C, 55.22; H, 4.22; N,
8.04; S, 9.19.
5.2.1.8. N-(4-Hydroxyphenyl)-4-[2,3-dihydro-3-oxo-1,2-
benzisothiazol-2-yl-1,1-dioxide]-butyrylamide (5c). A solu-
tion of 4-chloro-N-(4-hydroxyphenyl)-butyrylamide (3c,
5.8 g, 27 mmol), anhydrous sodium saccharin (4, 8.4 g,
41 mmol) and NaI (0.85 g, 5.6 mmol) in dry DMF
(20 mL)was heated to 90 C for 1.5 h. The reactionwas al-
lowed to cool to room temperature, the precipitate was ﬁl-
tered, and the ﬁltrate was evaporated under reduced
pressure. The residue was dissolved in EtOAc (280 mL),
washed, respectively, with water (100 mL) and brine solu-
tion (100 mL), and dried (Na2SO4). The solvent was re-
moved under reduced pressure and the white solid
residue was recrystallized in ethanol/H2O (10:1) to furnish
5c as awhite crystalline solid (7.9 g, 82%).Mp 190–192 C.
1H NMR (DMSO-d6, 400 MHz) d: 9.57 (s, 1H, NH), 9.06
(s, 1H,OH), 8.25–7.95 (m, 4H,H-4,5,6,7 of 2-[2,3-dihydro-
3-oxo-1,2-benzisothiazol-2-yl-1,1-dioxide]), 7.33 (d, 2H,
8.8. Hz, H-2,6 p-aminophenol), 6.70 (d, 2H, 8.8 Hz, H-
3,5 p-aminophenol), 3.78 (t, 2H, 7.4 Hz, C(a)H2), 2.37 (t,
2H, 7.4 Hz, C(v)H2), 2.02 (m, 2H, C(b)H2). Anal. Calcd
for C17H16N2O5S: C, 56.66; H, 4.44; N, 7.77; S, 8.90.
Found: C, 56.72; H, 4.47; N, 7.75; S, 8.81.
5.2.2. Method B
5.2.2.1. General procedure for the synthesis of 2-(2,3-
dihydro-3-oxo-1,2-benzisothiazol-2-yl-1,1-dioxide)alkane-
carboxylic acids (7). A solution of anhydrous sodium
saccharin (4, 8.6 g, 42 mmol) and the corresponding
x-haloalkanecarboxylic acid (6, 4.5 g, 25 mmol) in
DMF (20 mL) was heated to reﬂux for 3 h. The reaction
mixture was allowed to cool to room temperature, the
precipitate was ﬁltered, and the ﬁltrate was evaporated
under reduced pressure. The residue was dissolved in
EtOAc (200 mL), washed with brine (2· 130 mL), and
dried (Na2SO4). The solvent was removed under
reducedpressure and thewhite solid residuewas recrystal-
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solid.5.2.2.2. 5-(2,3-Dihydro-3-oxo-1,2-benzisothiazol-2-yl-
1,1-dioxide)pentanoic acid (7a). The general method was
applied to 5-bromopentanoic acid (6a, 4.5 g, 25 mmol) to
furnish 7a as a crystalline solid (5.0 g, 71%). Mp 82 C.
IR (KBr, cm1); 2955, 2866, 1701, 1459, 1411, 1333,
1290, 1258, 1182, 1059, 923, 749. 1H NMR (CD3OD,
300 MHz) d: 7.93–7.72 (m, 4H, H-4,5,6,7 of 2-[2,3-dihy-
dro-3-oxo-1,2-benzisothiazol-2-yl-1,1-dioxide]), 3.63 (t,
2H, J = 6.6 Hz, C(a)H2), 2.22 (t, 2H, J = 7.3 Hz,
C(d)H2), 1.78–1.48 (m, 4H, C(b)H2, C(v)H2). Anal. Calcd
for C12H13NO5S.H2O:C, 47.83;H, 5.02; N, 4.65; S, 10.62.
Found: C, 47.55; H, 4.92; N, 5.54; S, 10.50.
5.2.2.3. 6-(2,3-Dihydro-3-oxo-1,2-benzisothiazol-2-yl-
1,1-dioxide)hexanoic acid (7b).Thegeneralmethodwas ap-
plied to 6-bromohexanoic acid (6b, 4.9 g, 25 mmol) to yield
7b as a crystalline solid. Mp 93 C. IR (KBr, cm1): 2955,
2866, 1701, 1459, 1411, 1333, 1290, 1258, 1182, 1059, 923,
749. 1HNMR(CD3OD,300 MHz)d: 8.08–7.93 (m,4H,H-
4,6,7 of 2-[2,3-dihydro-3-oxo-1,2-benzisothiazol-2-yl-1,1-
dioxide]), 3.76 (t, 2H, J = 7.3 Hz, C(a)H2), 2.31 (t, 2H,
J = 6.9 Hz, C(e)H2), 1.84 (m, 2H, CH2), 1.67 (m, 2H,
CH2), 1.45 (m, 2H, CH2). Anal. Calcd for C13H15NO5SÆ-
H2O: C, 49.52; H, 5.43; N, 4.44; S, 10.15. Found: C,
49.20, H, 4.99; N, 4.48; S, 10.02.
5.2.2.4. General procedure for the synthesis of N-(4-
hydroxyphenyl)-2-[2,3-dihydro-3-oxo-1,2-benzisothiazol-
2-yl-1,1-dioxide]-alkanecarboxamides (5). To a solution
containing the corresponding acid 7 (20 mmol), 4-ami-
nophenol (2, 2.2 g, 20 mmol), and 1-hydroxy-1H-benzo-
triazole (2.7 g) in CH2Cl2, (80 mL) previously cooled to
0 C, a solution of 1,3-dicyclohexylcarbodiimide (4.1 g,
20 mmol) in CH2Cl2 (30 mL) was added. After the addi-
tion was completed, the reaction mixture was stirred at
room temperature for 2 h. The resulting solid was ﬁl-
tered and recrystallized from ethanol/water (10:1) to fur-
nish the corresponding 5 as a white crystalline solid.
5.2.2.5. N-(4-Hydroxyphenyl)-5-[2,3-dihydro-3-oxo-1,2-
benzisothiazol-2-yl-1,1-dioxide]-pentamide (5d). The gener-
al method was applied to the acid 7a (5.6 g, 20 mmol), to
obtain 5d as a white crystalline solid (4.1 g, 54%). Mp
162–164 C. IR (KBr, cm1); 3324, 1722, 1661, 1547,
1521, 1323, 1312, 1184. 1H NMR (DMSO-d6, 300 MHz)
d: 9.63 (s, 1H, NH), 9.06 (s, 1H, OH), 8.32 (d, 1H,
J = 7.2 Hz, H-4 of 2-[2,3-dihydro-3-oxo-1,2-ben-
zisothiazol-2-yl-1,1-dioxide]), 8.12–7.95 (m, 3H, H-5,6,7
of 2-[2,3-dihydro-3-oxo-1,2-benzisothiazol-2-yl-1,1-diox-
ide]), 7.25 (d, 2H, J = 8.8 Hz, H-2,6 p-aminophenol), 6.67
(d, 2H, J = 8.8 Hz, H-3,5 p-aminophenol), 3.71 (t, 2H,
J = 6.8 Hz, C(a)H2), 2.33 (t, 2H, J = 6.2 Hz, C(d)H2),
1.71–1.64 (m, 4H, C(b)H2, C(v)H2). Anal. Calcd for
C18H18N2O5S: C, 57.74; H, 4.85; N, 7.48; S 8.56. Found:
C, 57.99; H, 4.88; N, 7.42; S, 8.44.
5.2.2.6. N-(4-Hydroxyphenyl)-6-[2,3-dihydro-3-oxo-
1,2-benzisothiazol-2-yl-1,1-dioxide]-hexamide (5e). The
general method was applied to the acid 7b (5.9 g,20 mmol), to obtain 5e as a white crystalline solid
(4.6 g, 59%). Mp 131–133 C. IR (KBr, cm1); 3319,
1721, 1661, 1552, 1335, 1322, 1181. 1H NMR (DMSO-
d6, 300 MHz) d: 9.58 (s, 1H, NH), 9.09 (s, 1H, OH),
8.29 (d, 1H, J = 7.7 Hz, H-4 of 2-[2,3-dihydro-3-oxo-
1,2-benzisothiazol-2-yl-1,1-dioxide]), 8.12–7.95 (m, 3H,
H-5,6,7 of 2-[2,3-dihydro-3-oxo-1,2-benzisothiazol-2-yl-
1,1-dioxide]), 7.27 (d, 2H, J = 8.4 Hz, H-2,6 p-amino-
phenol), 6.71 (d, 2H, J = 8.6 Hz, H-3,5 p-aminophenol),
3.73 (t, 2H, J = 7.0 Hz, C(a)H2), 2.27 (t, 2H, J = 7.0 Hz,
C(e)H2), 1.77–1.72 (m, 2H, C(b)H2), 1.63-1.57 (m, 2H,
C(v)H2), 1.39–1.34 (m, 2H, C(d)H2). Anal. Calcd for
C19H20N2O5S: C, 58.75; H, 5.11; N, 7.01; S, 8.25.
Found: C, 58.57; H, 5.24; N, 7.28; S, 8.13.
5.2.3. Hydrolysis of 5b
5.2.3.1. 2-{[(4-Hydroxyphenylcarbamoyl)methyl]sulfa-
moyl}benzoic acid (8). Two grams of 5a (6 mmol) was
suspended in 10 mL of 10% aqueous NaOH, and after
30 min, suspension turned into a solution. Then 8 was
isolated by neutralization of the reaction mixture with
1 N HCl and extraction with ethyl acetate. 2 g of 6
was obtained (98%). Mp 193–195 C. IR (KBr, cm1);
3364, 3320, 2969, 1701, 1642, 1610, 1537, 1400, 1331,
1271, 1157, 1108. 1H NMR (DMSO-d6, 300 MHz) d:
13.50 (br s, 1H, COOH); 9.70 (s, 1H, CONH); 9.18 (br
s, 1H, OH); 7.94 (d, 1H, J = 7.8 Hz, H-6 benzoic acid);
7.74–7.67 (m, 3H, H-4,5 benzoic acid+SO2NH); 7.39
(br s, 1H, H-3 benzoic acid); 7.20 (d, 2H, J = 8.4 Hz,
H-2,6 p-aminophenol); 6.65 (d, 2H, J = 8.4 Hz, H-3,5
p-aminophenol); 3.73 (s, 2H, CH2). Anal. Calcd for
C15H14N2O6S: C, 51.42; H, 4.03; N, 8.00; S 9.15. Found:
C, 51.30; H, 4.14; N, 8.11; S, 9.03.
5.3. Biology
5.3.1. Analgesic assays. All tests were performed on male
CD-1 mice (25–35 g; Charles River Breeding Laborato-
ries, Wilmington, MA). Compounds 5 (St. Charles
Pharmaceuticals, New Orleans, LA), or APAP (Sigma,
St. Louis, MO) in amounts as established in speciﬁc pro-
tocols was suspended in the vehicle (Agent K, 0.2%, Bio-
serve, or Labraﬁl 1944, Gottefosee, France). Drugs or
vehicle was administered per os (po) by esophageal can-
nulation under brief halothane anesthesia to animals
fasted overnight.
5.3.2. Chemically induced writhing.18 In this model of vis-
ceral pain, abdominal contractions (writhing) were in-
duced in mice by an intraperitoneal (ip) injection of
0.4% acetic acid at a dose of 10 mL/kg 25 min after drug
administration. The numbers of writhes, characterized
by a wave of contraction of the abdominal muscles fol-
lowed by extension of the hind limbs, were counted for
10 min beginning 5 min after the acetic acid injection.
Data were analyzed using a two-way ANOVA (drug ·
dose), followed by Tukey’s post hoc comparisons.
5.3.3. Formalin-induced pain.20Mice were injected subcu-
taneously (sc) into the plantar surface of one hind paw
with 30 lL of 5% buﬀered formalin acetate 30 min after
drug administration. The amount of time the animal
spent licking the injected paw was recorded for blocks
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Animal behavior was observed with the help of a mirror
positioned at a 45 angle under a specially designed clear
Plexiglas cage (16 · 32 · 32 cm), which allowed an unob-
structed view of the animal’s paw. To minimize stress,
mice were habituated to the test box for 90 min on the
day before testing. Data in the formalin assay were ana-
lyzed using a three-way ANOVA (drug · dose · time),
followed by Tukey’s post hoc comparisons.
5.3.4. Tail-ﬂick test.21 The tail of each mouse was ex-
posed to a focused beam of light and the latency to re-
move the tail from the path of the stimulus was
recorded electronically using a photoelectric cell. The
stimulus intensity was adjusted to produce baseline
latencies of 3–4 s.
5.3.5. Hot plate test.22 Each mouse was placed on a hot
plate (54 ± 1 C) and the latency to lick the hind paw was
recorded. Mice not responding after 30 s were removed
and assigned a latency of 30 s. All the experiments were
performed in ‘blind’ fashion. ED50 values were deter-
mined using nonlinear regression analyses.
5.3.6. Carrageenan-induced paw edema.24 Under halo-
thane anesthesia male CD-1 mice were injected with
lambda-carrageenan (50 lL, 1% in saline; Sigma)
via the plantar surface of one hind paw 30 min after drug
administration. Inﬂammation (paw volume: model 520
paw volume meter; IITC Life Sciences, Inc., Woodland
Hills, CA.) was measured before and 4 h after injection
of carrageenan. Indomethacin (30 mg/kg, po), a known
anti-inﬂammatory, was used as a ‘positive control.’
5.3.7. Glutathione depletion.29 Male CD-1 mice (20–30 g;
Charles River Breeding Laboratories, Wilmington, MA)
were treatedwith 6 mmol/kg 5aorAPAP, or vehicle as de-
scribed above (in a pilot study, 6 mmol/kgwas established
as the LD50 for APAP). Three hours after drug adminis-
tration, mice from diﬀerent treatment groups were killed
and the livers perfused with heparinized saline. The right
hemisphere was dissected and homogenized using a Tef-
lon pestle in MPA (5% w/v) to a concentration of 5%
(w/v). Kidneys also were removed and homogenized with
MPA (5% w/v) to a concentration of 10% (w/v). The
homogenates were centrifuged for 10 min at 3000g at
4 C, and glutathione levels were measured in 300-lL ali-
quots of the supernatant using a colorimetric assay kit
(Calbiochem, La Jolla, CA).
5.3.8. Serum transaminase activity.19,25 Twenty-four
hours after drug treatment, mice were decapitated and
blood withdrawn into 1-cc heparinized syringes. Plasma
was obtained by centrifugation of blood samples at
3000 rpm for 10 min at 4 C. The plasma glutamic–
pyruvic transaminase (GPT) and glutamic–oxaloacetic
transaminase (GOT) levels were determined by a Spec-
trophotometric test kit (Sigma). Mortality rate was
recorded 24 h after drug administration.
5.3.9. HEPG-2 cells and human hepatocytes. HEPG-2
cells were grown and maintained in EMEM containingNEAA (non-essential amino acids), supplemented with
10% fetal bovine serum (FBS), and incubated at 37 C
with a constant supply of 5% CO2. Primary human liver
cells were grown in HCM (Clonetics,Walkersville, MD),
and maintained in HMM (Clonetics, Walkersville, MD)
at 37 C with 5% CO2. Cultures (80% conﬂuent) of
HEPG-2 and primary hepatocytes growing in 6- and
24-well plates, respectively, were held 6–8 h in serum-
free medium (EMEM, 0.5% FBS for HEPG-2, and
HMM for primary hepatocytes) before the addition of
analgesics. The serum-starved cells were treated with
5a, APAP, or a nitrate ester derivative of acetamino-
phen (NO-APAP) for 6–8 h at 37 C.
5.3.10. Hoechst staining for detection of apoptosis. Spent
medium was removed from the experimentally treated
cells, which were washed with 2 mL PBS (room temper-
ature). Hoechst solution (2 mL, 2 lM ﬁnal concentra-
tion) was added to the cells, and they were incubated
at 37 C for 45 min. Apoptotic cell death was detected
by confocal microscopy under ﬂuorescence illumination.
5.3.11. Western-blot analysis. The up-regulation of Fas-
ligand (Fas-L) and activation of CAR (constitutive
androstane receptor) were analyzed by Western blot.
Brieﬂy, the cell extracts were made and adjusted for pro-
tein concentrations by Bio-Rad method. About 15-20 lg
protein was loaded onto an 8–16% gel (Invitrogen, Carls-
bad, CA.), and electrophoresis was conducted for 2 h at
125 V. The proteins were transferred onto nitrocellulose
membrane at 30 V for 60 min at 4 C. The membranes
were probed with either Fas-L- or CAR (human)-speciﬁc
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA)
and phosphorylation of the Fas-L and CAR was detect-
ed by ECL kit. Quantitation of Fas-L and CAR proteins
was performed by densitometry.
5.3.12. Determination of metabolites. Two-month-old
CD-1 mice were fasted overnight. Next morning, follow-
ing light halothane anesthesia, they were given po 5a,
3 mmol/kg in Tween 20 (vehicle). They were placed in
Nalgene metabolic cages (two mice per cage) with water
ad libitum. Food was supplied 6 h post dose treatment.
The urine was collected in a plastic container, which was
maintained in ice during the 24-h collecting period. It
was stored at 20 C until use. At the time of the HPLC
injection, aliquots were centrifuged in a microfuge at
6000 rpm, 15 C for 10 min, ﬁltered with nylon ﬁlters
(0.45 lm), and used immediately or lyophilized.
In the HPLC–MS analysis, a volume of 20 lL was inject-
ed. When lyophilized samples were used, they were dis-
solved in a mixture of acetonitrile–0.1% ammonium
acetate solution, pH 7 (50:50, v/v). The HPLC-MS anal-
yses were performed in an Agilent 1100 apparatus. The
analytical column was a Luna 150 · 4.6 mm, C18
(5 lm) Phenomenex column. The mobile phase was de-
gassed automatically by the electronic degasser system.
Before the analysis, the column was equilibrated and a
gradient program was used for analysis of samples. The
ﬂow rate was maintained at 1.5 mL/min and the column
was maintained at 45 C. The linear gradient mobile
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and 15% acetonitrile at 0 min; 10% ammonium acetate
buﬀer (pH 3.6) and 90% acetonitrile at 17 min. When a
UV detector was used, the wavelength of detection was
set at 280, 254, and 210 nm. Peak width, response time,
and slit were set at >0.03 min, 0.5 s, and 8 nm, respective-
ly. In the MS detector, the capillary voltage
was ± 2500 V, the drying gas temp was 350 C, the nebu-
lizer pressure was 30 psig, drying gas ﬂow was 12 L/min,
and the fragmentor was at 70 eV, with a mass range of
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